Details

Autor(en) / Beteiligte

• Heise, Tim, MD
• Jordan, Jens, MD
• Wanner, Christoph, MD
• Heer, Martina, PhD
• Macha, Sreeraj, PhD
• Mattheus, Michaela, Dipl Biomath
• Lund, Søren S., MD
• Woerle, Hans J., MD
• Broedl, Uli C., MD

Titel

Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes

Ist Teil von

• Clinical therapeutics, 2016-10, Vol.38 (10), p.2265-2276

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2016

Quelle

MEDLINE

Beschreibungen/Notizen

• Abstract Purpose Our aim was to investigate the effects of the sodium glucose cotransporter 2 inhibitor empagliflozin on urinary and serum glucose and electrolytes, urinary volume, osmolality, and the renin−angiotensin system in patients with type 2 diabetes. Methods In an open-label study, 22 patients receiving metformin (median age 56 years; range 40–65 years) received empagliflozin 25 mg once daily for 5 days. Food, fluid, and sodium intake were standardized for 3 days before and during treatment. Findings Twenty patients completed treatment. After single and multiple doses of empagliflozin, mean (SE) changes from baseline in 24-hour urinary glucose excretion were 463.3 (57.3) mmol/d and 599.5 (60.0) mmol/d, respectively (83.5 [10.3] g/d and 108.0 [10.8] g/d, respectively) (both P < 0.001), and in fasting serum glucose concentration were −1.8 (0.4) mmol/L and −1.1 (0.3) mmol/L, respectively (both P < 0.001). After a single dose, mean (SE) change from baseline in urine sodium excretion was 45.3 (9.6) mmol/d ( P < 0.001), and in urine volume was 341.0 (140.5) g/d ( P = 0.025), but there were no changes compared with baseline in either parameter after multiple doses. There were no changes in plasma renin or serum aldosterone with single or multiple doses of empagliflozin. There was a nonsignificant reduction in weight after a single dose of empagliflozin and a mean (SE) change of − 1.4 (0.5) kg after multiple doses ( P = 0.020). Implications Empagliflozin 25 mg increased urinary glucose excretion and decreased serum glucose and weight with transient natriuresis and increases in urine volume, without significant changes in the renin−angiotensin system. Clinicaltrials.gov Identifier: NCT01276288.